Loading organizations...
§ Private Profile · 600 Chesapeake Dr, Redwood City, California, 94063, United States
Medical device company developing transcervical technologies for symptomatic uterine fibroids, including the Sonata System.
Gynesonics, based in Redwood City, CA, develops minimally invasive, incision-free, uterus-preserving transcervical technologies for women's health, primarily focusing on symptomatic uterine fibroids. Its flagship Sonata System is the first FDA-cleared device for diagnostic intrauterine imaging and transcervical radiofrequency ablation treatment of these fibroids. The company has successfully raised significant capital to support its mission, including $43 million in equity financing co-led by prominent investors Endeavour Vision and Abingworth. Additionally, Gynesonics secured an extra $25 million in financing in April 2023, specifically aimed at expanding the commercialization efforts for its Sonata System. The organization, which operates with 13 executives, is led by CEO Skip Baldino, appointed in March 2023, and was founded by Jessica Grossman. Its board of directors further strengthens its leadership with members like Susan Stimson and Amy Raimundo.
Gynesonics has raised $321.0M across 10 funding rounds.
Gynesonics has raised $321.0M in total across 10 funding rounds.
Gynesonics has raised $321.0M across 10 funding rounds. Most recently, it raised $42.5M Other Equity in November 2023.
Gynesonics is a medical technology company specializing in minimally invasive, incisionless treatments for women's health, particularly symptomatic uterine fibroids.[1][2][3] Its flagship product, the Sonata System, is the first FDA-cleared device for diagnostic intrauterine imaging and transcervical radiofrequency ablation, offering a uterus-preserving alternative to hysterectomy or myomectomy for women worldwide.[2][4][5][6] The company serves gynecologists and patients affected by fibroids—impacting up to 80% of women under 50—by solving the problem of invasive surgeries through ultrasound-guided, incision-free procedures that improve symptoms and quality of life, as evidenced by over 10,000 treatments globally by August 2024.[2][4] Growth momentum includes recent software upgrades like SMART OS 2.4 for enhanced precision and Hologic's acquisition, integrating it into a global women's health leader.[4][5][7]
Founded to advance women's health through transcervical technologies, Gynesonics emerged with a focus on incision-free options for uterine fibroids, headquartered in Redwood City, California.[1][2][3] While specific founders are not detailed in available sources, the company pioneered the Sonata System, achieving FDA clearance as the first device for intrauterine imaging and transcervical treatment.[2][5][6] Early traction built through clinical validation, culminating in milestones like the 10,000th patient treatment in 2024 and ongoing innovations such as SMART OS software updates, demonstrating steady evolution toward broader adoption.[2][4]
Gynesonics rides the trend toward minimally invasive women's health solutions, addressing a massive market where uterine fibroids affect up to 80% of women under 50, amid rising demand for uterus-preserving alternatives to hysterectomies.[2][4] Timing aligns with advances in ultrasound-guided therapies and radiofrequency ablation, amplified by FDA clearances and global partnerships that expand access.[2][6] Market forces like growing awareness of fibroid impacts on quality of life and Hologic's acquisition favor scaled distribution, influencing the ecosystem by elevating incisionless standards and inspiring further medtech innovation in gynecology.[5][7]
Gynesonics' integration into Hologic positions the Sonata System for accelerated global rollout, with software enhancements like SMART OS driving precision and adoption.[4][5][7] Trends in personalized, non-surgical women's health—fueled by AI-guided imaging and ablation—will shape its path, potentially expanding indications beyond fibroids. Its influence may evolve from pioneer to ecosystem standard-setter, offering more women effective alternatives and reinforcing Gynesonics' legacy in revolutionizing care.[1][2]
Gynesonics has raised $321.0M in total across 10 funding rounds.
Gynesonics's investors include Joyce Erony, Bain Capital, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, Hugo Harrod, Robert Lake, Bain Capital Life Sciences, Ken Haas, Mike Carusi, Correlation Ventures, HBM Partners.